Article
Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease.
Department of Geriatrics, University of Foggia, Ospedali Riuniti, Viale L. Pinto, 71100 Foggia, Italy.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (impact factor:
3.25).
11/2009;
34(1):177-82.
DOI:10.1016/j.pnpbp.2009.10.022
pp.177-82
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
[show abstract] [hide abstract]
ABSTRACT: About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between variations in specific candidate genes and the positive and adverse effects of drug treatment. Approximately, 18% of neuroleptics are substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4. 10-20% of Western populations are defective in genes of the CYP superfamily; and the pharmacogenomic response of psychotropic drugs also depends on genetic variants associated with dementia. Prospective studies with anti-dementia drugs or with multifactorial strategies have revealed that the therapeutic response to conventional drugs in Alzheimer’s disease is genotype-specific. The disease-modifying effects (cognitive performance, biomarker modification) of therapeutic intervention are APOE-dependent, with APOE-4 carriers acting as the worst responders (APOE-3/3 > APOE-3/4 > APOE-4/4). APOE-CYP2D6 interactions also influence the therapeutic outcome in patients with dementia.Pharmaceuticals. 01/2010;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
-174G/C single-nucleotide polymorphism
149 AD patients
3' flanking region
additive effect
APOE epsilon4 status
apolipoprotein E
chromosome 7
conflicting results
delayed onset
haplotype analysis
IL-6 variable number
IL-6 VNTR
IL-6 VNTR polymorphisms
IL-6)-174 C/G polymorphism
late-onset
sex-matched unrelated caregivers
sporadic AD
total sample
VNTR polymorphism
weak genetic determinants